Odyssey Therapeutics, Inc. Common Stock
ODTXStock
$18.47
Market Cap$887.14M
P/E—
Div yield—
Beta1.45
Price Chart
Favorite Metrics
Price vs S&P 500 (4W)7.90%
VGM Score81.94
Market Capitalization$887.14M
Industry Peers — Biological Products(180)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ODTXOdyssey Therapeutics, Inc. Common Stock | — | A | B | $18.47 |
| AMGNAmgen Inc | C | C | C | $351.43 |
| GILDGilead Sciences Inc | C | B | C | $125.16 |
| ARGXargenx SE American Depositary Shares | D | A | B | $852.50 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $169.77 |
| BIIBBiogen Inc. Common Stock | B | D | B | $199.59 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $90.21 |
| MRNAModerna, Inc. Common Stock | D | B | A | $60.42 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $166.06 |
| EXELExelixis Inc | C | B | B | $52.87 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | A | $347.63 |
About
Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.